Global Blood Therapeutics, Inc. (NASDAQ:GBT – Get Rating) – Investment analysts at Cantor Fitzgerald issued their FY2022 earnings estimates for Global Blood Therapeutics in a research report issued on Wednesday, September 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($4.55) per share for the year. Cantor Fitzgerald currently has a “Neutral” […]